Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Active, not recruiting · NCT06596252 · Registry updated 2026-08-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder | Active, not recruiting | Phase 3 | 2026-08-28 | NCT06596252 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dr. Falk Pharma GmbH | 3 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Gastroenterology, Hospital General de Tomelloso | Tomelloso | Spain | 1 |
| Wyoming | Ann Arbor | United States | 1 |
| Wyoming | Philadelphia | United States | 1 |